Technology | December 06, 2012

FDA Clears HeartWare Ventricular Assist Device

HeartWare VAS offers bridge to heart transplant

December 6, 2012 — The U.S. Food and Drug Administration (FDA) granted premarket approval (PMA) for the HeartWare Ventricular Assist System (VAS) designed as a bridge to cardiac transplantation.

The HeartWare Ventricular Assist System (VAS) is a device that helps deliver blood from the heart to the rest of the body. It is used in some patients who have end-stage heart failure and are waiting for a heart transplant. The system includes a pump implanted in the space around the heart (pericardium) and a controller that controls the speed and function of the pump. The controller remains outside the patient’s body and is connected to the pump by a flexible tube that passes through the patient’s skin. The controller is powered either by batteries or a power supply that can be connected to a standard electrical power outlet.

The system works with the patient’s own heart to pump blood. In a healthy heart, the lower chamber (left ventricle) pumps blood through the body. In a heart weakened by heart failure, the left ventricle may not be strong enough to pump the blood sufficiently. The HeartWare VAS helps the heart by supporting the weak left ventricle and providing additional blood flow.

Blood flows from the left ventricle into the pump through the pump inlet. The pump then moves blood into the aorta. This is accomplished by the rotation of the pump's impeller, which speeds up the blood flow and also causes a difference in pressure between the pump inlet and outlet.

Because there are a limited number of donor hearts available, the HeartWare VAS provides necessary cardiac support to the patient until a suitable heart is available. This is often called bridge to transplantation. The HeartWare VAS is used as a bridge to transplantation in cardiac transplant candidates at risk of death from end-stage heart failure that is unmanageable by standard medical therapy. The device is designed for in-hospital and out-of-hospital settings, including transportation by fixed-wing aircraft or helicopter.

The FDA said a clinical trial showed that treatment with the HeartWare VAS kept the majority of patients alive long enough to receive a heart transplant. In the study, 127 out of 140 patients (91 percent) either survived for at least 180 days on the pump (without having to get a new pump) or received a heart transplant within that time. Six (6) out of the 140 patients (4 percent) died within 180 days of being implanted with their first HeartWare VAS.

As with any major surgery, there are risks involved with the surgery to implant the HeartWare device. There are also risks and complications with the device itself, and these include death, stroke, infections, and bleeding.

The HeartWare VAS should not be used in patients who cannot tolerate blood thinners (anticoagulation therapy) because these medications are required to prevent blood clots from forming in the pump.

The FDA set expiration dating for this device at 25 months for the implant kit, accessories and surgical tools of the system, and 12 months for the controller and battery pack.

In addition to the FDA’s annual report requirements, HeartWare must provide additional data on newly implanted patients in an ongoing post-market study. The study will consist of prospective enrollment of patients newly implanted with the HeartWare VAS and who may also be concurrently enrolled in the INTERMACS Registry.  At least 1,200 patients (600 HeartWare and 600 FDA-approved VADS other than HeartWare) patients from at least 12 sites in the United States will be followed annually according to standard of care through 24 months. The primary endpoints will be success based on those who are alive, transplanted or recovered at 180 days.

For more information:




Related Content

Trial Data Shows Positive Predictive Results for Boston Scientific HeartLogic Heart Failure Diagnostic
News | Heart Failure| October 20, 2017
October 20, 2017 — Boston Scientific announced new data from the Multisensor Chronic Evaluation in Ambulatory Heart F
Pregnancy-Related Heart Failure Strikes Black Women Twice as Often as Other Races
News | Womens Healthcare| October 19, 2017
African American women were found to be twice as likely to be diagnosed with peripartum cardiomyopathy as compared to...
The Respicardia Remede System is a pacemaker-like device designed to improve cardiovascular health by restoring natural breathing during sleep in patients with Central sleep apnea.
Technology | Heart Failure| October 18, 2017
October 18, 2017 — The U.S.
First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Low Mortality and Stroke Risks Displayed for Minimally Invasive Aortic Valve Replacements
News | Heart Valve Technology| October 11, 2017
An analysis of more than 1,000 minimally invasive aortic valve replacements and more than 400 additional associated...
Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD)| October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD)| September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Boston Scientific Launches Resonate Devices With HeartLogic Heart Failure Diagnostic
Technology | Implantable Cardioverter Defibrillator (ICD)| September 27, 2017
September 27, 2017 — Boston Scientific recently launched the Resonate family of...
BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies| September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
CardiAMP Heart Failure Trial Design Presented at Texas Heart Institute Symposium
News | Heart Failure| September 25, 2017
BioCardia Inc. announced the trial design for its pivotal Phase III CardiAMP Heart Failure Trial was presented during...
Overlay Init